Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Bausch & Lomb Corp (BLCO)
Bausch & Lomb Corp (BLCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,382,223
  • Shares Outstanding, K 350,862
  • Annual Sales, $ 3,768 M
  • Annual Income, $ 6,000 K
  • 60-Month Beta 0.20
  • Price/Sales 1.41
  • Price/Cash Flow 6.94
  • Price/Book 0.77
Trade BLCO with:
  • Price/Earnings ttm 20.78
  • Earnings Per Share ttm 0.73
  • Most Recent Earnings 0.22 on 11/01/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-3851 Ophthalmic Goods

    Medical Services

Options Overview Details

View History
  • Implied Volatility 37.31% ( -0.27%)
  • Historical Volatility 31.48%
  • IV Percentile 15%
  • IV Rank 29.28%
  • IV High 107.01% on 09/15/23
  • IV Low 8.45% on 09/07/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 13
  • Volume Avg (30-Day) 173
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 10,439
  • Open Int (30-Day) 10,240

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.17
  • Number of Estimates 5
  • High Estimate 0.21
  • Low Estimate 0.12
  • Prior Year 0.23
  • Growth Rate Est. (year over year) -26.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.77 +6.03%
on 11/29/23
16.55 -5.38%
on 11/09/23
-0.84 (-5.09%)
since 11/08/23
3-Month
14.77 +6.03%
on 11/29/23
17.92 -12.59%
on 09/12/23
-1.58 (-9.16%)
since 09/08/23
52-Week
14.37 +8.98%
on 12/22/22
21.95 -28.66%
on 06/30/23
+0.41 (+2.69%)
since 12/08/22

Most Recent Stories

More News
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

OKYO : 1.6700 (-1.76%)
ALC : 71.99 (+0.13%)
BLCO : 15.66 (+2.09%)
JNJ : 154.42 (-0.63%)
RHHBY : 36.0000 (+1.18%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...

OKYO : 1.6700 (-1.76%)
ALC : 71.99 (+0.13%)
BLCO : 15.66 (+2.09%)
JNJ : 154.42 (-0.63%)
RHHBY : 36.0000 (+1.18%)
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better,...

BLCO : 15.66 (+2.09%)
BLCO.TO : 21.26 (+1.87%)
Bausch + Lomb Releases Annual Environmental, Social and Governance Report

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better,...

BLCO : 15.66 (+2.09%)
BLCO.TO : 21.26 (+1.87%)
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 podium...

BLCO : 15.66 (+2.09%)
BLCO.TO : 21.26 (+1.87%)
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election...

BLCO : 15.66 (+2.09%)
BLCO.TO : 21.26 (+1.87%)
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™...

BLCO : 15.66 (+2.09%)
BLCO.TO : 21.26 (+1.87%)
Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of eight scientific...

BLCO : 15.66 (+2.09%)
BLCO.TO : 21.26 (+1.87%)
Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and...

BLCO : 15.66 (+2.09%)
BLCO.TO : 21.26 (+1.87%)
Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial...

BLCO : 15.66 (+2.09%)
BLCO.TO : 21.26 (+1.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R)....

See More

Key Turning Points

3rd Resistance Point 16.36
2nd Resistance Point 16.03
1st Resistance Point 15.84
Last Price 15.66
1st Support Level 15.32
2nd Support Level 14.99
3rd Support Level 14.80

See More

52-Week High 21.95
Fibonacci 61.8% 19.05
Fibonacci 50% 18.16
Fibonacci 38.2% 17.27
Last Price 15.66
52-Week Low 14.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar